Related Experiment Video
Updated: Apr 24, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies
Ira Surolia1, James Gulley, Ravi A Madan
1National Institute of Health , Bethesda, MD , USA.
Introduction:
Despite a recent increase in US FDA-approved treatments, genitourinary malignancies remain a source of significant morbidity and mortality. One focus of research is the use of therapeutic cancer vaccines in these diseases, and a significant body of clinical trial experience now exists for refining vaccine strategies to enhance antitumor efficacy and develop immune-based combination regimens.
Areas Covered:
In recent years, clinical data from multiple trials in genitourinary malignancies have enhanced our understanding of the potential for immunotherapy in these cancers. There are also emerging clinical strategies that combine cancer vaccines with chemotherapy, radiation, androgen-deprivation therapy and immune checkpoint inhibitors. This review is based on a search of relevant literature for data presented over the past 5 years from clinical trials of cancer vaccines in prostate, bladder and renal carcinomas.
Expert Opinion:
In the coming years, clinical trials informed by decades of preclinical data and emerging clinical data will help to define the role of immunotherapy in genitourinary malignancies. Combination strategies that capitalize on the immune properties of standard treatments will bring greater clinical benefits, and immune-based combinations will likely be moved to the neoadjuvant setting, where they may have optimal clinical impact.
Insights
Therapeutic cancer vaccines show promise for genitourinary malignancies. Combining these vaccines with other treatments like chemotherapy and immunotherapy may improve patient outcomes.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Genitourinary malignancies cause significant morbidity and mortality despite advances in treatment.
- Therapeutic cancer vaccines are an area of active research for these cancers.
- Extensive clinical trial data exists for refining vaccine strategies.
Purpose of the Study:
- To review recent clinical trial data on cancer vaccines in genitourinary cancers.
- To explore emerging combination strategies for immunotherapy.
- To understand the evolving role of immunotherapy in prostate, bladder, and renal carcinomas.
Main Methods:
- Literature search for clinical trial data over the past 5 years.
- Focus on trials involving cancer vaccines in prostate, bladder, and renal carcinomas.
- Analysis of combination regimens including chemotherapy, radiation, and immune checkpoint inhibitors.
Main Results:
- Clinical data has improved understanding of immunotherapy potential in genitourinary cancers.
- Combination strategies integrating vaccines with standard therapies are emerging.
- Evidence suggests enhanced antitumor efficacy with refined vaccine strategies.
Conclusions:
- Immunotherapy, particularly cancer vaccines, will play a defined role in genitourinary malignancies.
- Combination strategies leveraging standard treatments' immune properties offer greater clinical benefits.
- Neoadjuvant immune-based combinations may provide optimal clinical impact.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers